摘要
目的寻找卵巢癌患者血清中新的肿瘤标志物。方法采用表面增强激光解吸/离子化飞行时间质谱（SELDI—TOF—MS）技术，选用WXC2蛋白质芯片对53例卵巢癌及50例对照血清标本进行检测以筛选卵巢癌患者血清中差异表达蛋白质。结果在分子量0-50000D范围内，检测出275个差异蛋白峰。卵巢癌差异表达明显的蛋白峰6个（P〈0．05），其中低表达的5个，相对分子量分别为6432、6879、8554、8682、13726D，高表达的1个，相对分子质量为11450D。早期与晚期卵巢癌比较，发现差异表达明显的蛋白峰2个，相对分子量分别为6190、6448D，均在早期卵巢癌中高表达。将发现的差异蛋白峰在Swiss蛋白数据库中搜索。发现11450D蛋白峰与S100 Zprotain相符。S100Z protem属于S100蛋白家族，可能通过与S100P相互作用，促进卵巢癌的发生。其它的差异峰在数据库中没有与之相匹配的蛋白，提示可能为新的蛋白质。结论SELDI—TOF—MS蛋白质芯片技术是1种快速、简单易行、用量少和高通量分析方法，能够直接检测出卵巢癌患者血清中相对特异的肿瘤标志物，其对于卵巢癌的早期诊断具有一定的临床意义。
Objective To search new serum tumor biomarkers for ovarian cancer. Methods Surfaceenhanced laser desorption/ionization time-of-flight mass spectrometry （SELDI-TOF-MS） WCX2 Proteinchip technology was used to detect biomarkers for ovarian cancer. Serum samples were from 53 patients with ovarian cancer, 50 from controls. Results Six proteins were specificly detected in sera of patients with ovarian cancer,but not in controls. Among them,five proteins with MW 6 432,6 879、8 554、8 682、 13 726 D were down-regulated,and one protein with MW 11 450 D was up-regulated. Comparing the early stage with the late stage of ovarian cancer,two proteins with MW 6 190,6 448 D were up-regulated in the early stage ovarian cancer. In Swiss-Prot database （http：//au. expasy, org/tools/tagident, html）,we found 11 450 D protein peak accord with S100 Z protein. S100 Z protein belongs to S100 protein family. Maybe through the interaction with SLOOP protein,it promoted the development of ovarian cancer. There were no proteins accordant with the other protein peaks,maybe they were new proteins. Conclusion SELDI-TOF-MS Proteinchip technology is a quick,easy and practical,high throughput analytic method. It can detect several specific markers from ovarian cancer sera, which had determinate clinical significance for the early diagnosis of ovarian cancer.
出处
《实用癌症杂志》
2006年第1期42-45,共4页
The Practical Journal of Cancer
